Insta
First Batch Of DRDO And Dr Reddy's 2-DG COVID-19 Drug To Be Launched Early Next Week
Swarajya Staff
May 15, 2021, 09:18 AM | Updated 09:18 AM IST
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
In a boost for the national efforts against the COVID-19 pandemic, the first batch of 2-deoxy-D-glucose (2-DG) drug will be launched next week, reports Livemint.
The drug has been developed by the DRDO lab, Institute of Nuclear Medicine and Allied Sciences, in collaboration with Hyderabad based pharmaceutical major Dr Reddy’s Laboratories to treat moderate to severe Covid-19 cases.
The 2-DG has been cleared by the Drug Controller General of India (DCGI) for emergency use in the treatment of Covid-19 patients earlier last week.
The first batch will comprise of 10,000 doses of 2-DG. It will be administered to patients as an adjunct therapy or an alternative treatment to assist the primary treatment.
A DRDO statement had earlier said that the clinical trial showed that the drug helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence. The patients treated with 2-DG showed faster symptomatic cure than Standard of Care (SoC) on various endpoints in the efficacy trends.
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
Introducing ElectionsHQ + 50 Ground Reports Project
The 2024 elections might seem easy to guess, but there are some important questions that shouldn't be missed.
Do freebies still sway voters? Do people prioritise infrastructure when voting? How will Punjab vote?
The answers to these questions provide great insights into where we, as a country, are headed in the years to come.
Swarajya is starting a project with an aim to do 50 solid ground stories and a smart commentary service on WhatsApp, a one-of-a-kind. We'd love your support during this election season.
Click below to contribute.